NCT07322406 Kaempferol Absorption and Pharmacokinetics Evaluation
| NCT ID | NCT07322406 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | No Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-12-09 |
| Primary Completion | 2026-12-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-12-09 with a primary completion date of 2026-12-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multi-site clinical trial designed to evaluate how the body absorbs and processes Kaempferol, a naturally occurring compound found in many plant-based foods. The primary purpose of the study is to measure the pharmacokinetics and biological absorption of Kaempferol in healthy adults. Participants will receive Kaempferol and undergo scheduled blood and urine collections over a short study period. These samples will be used to measure Kaempferol levels in the body and to assess safety and tolerability. In addition, selected biological samples will be analyzed to explore molecular changes associated with Kaempferol exposure using advanced laboratory methods. The study will be conducted at multiple research centers in the United States using a standardized protocol to ensure consistency across sites. The information collected will help improve understanding of how Kaempferol is absorbed and metabolized in humans and will support future research and regulatory evaluation.
Eligibility Criteria
Inclusion Criteria: Adults aged 18 to 70 years * Healthy volunteers as determined by medical history and screening assessment * Ability to understand the study procedures and provide informed consent * Willingness and ability to comply with all study procedures, including dietary restrictions, clinic visits, blood draws, urine collection, and follow-up assessments * Willingness to abstain from restricted foods, beverages, and supplements as specified in the study protocol during the study period Exclusion Criteria: * Known allergy or hypersensitivity to Kaempferol or related flavonoids * Pregnancy or breastfeeding * Presence of significant acute or chronic medical conditions that could increase risk or interfere with study outcomes, including but not limited to: * Active or chronic infections * Cancer * Cardiovascular disease * Neurological or neurodegenerative disorders * Metabolic or systemic inflammatory conditions * Use of prescription medications or supplements known to interfere with Kaempferol metabolism or pharmacokinetic assessment * Blood donation within 8 weeks prior to study enrollment * Participation in another interventional clinical study within a timeframe that could interfere with study results or participant safety * Any condition or circumstance that, in the judgment of the study investigator, would make participation unsafe or compromise data integrity
Contact & Investigator
Afshin Beheshti, PhD
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT07322406 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying No Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07322406 currently recruiting?
Yes, NCT07322406 is actively recruiting participants. Contact the research team at beheshti@pitt.edu for enrollment information.
Where is the NCT07322406 trial being conducted?
This trial is being conducted at New York, United States, Chapel Hill, United States, Pittsburgh, United States.
Who is sponsoring the NCT07322406 clinical trial?
NCT07322406 is sponsored by University of Pittsburgh. The principal investigator is Afshin Beheshti, PhD at University of Pittsburgh. The trial plans to enroll 120 participants.